OPHTHOTECH CORPORATION (NASDAQ:OPHT) Files An 8-K Other EventsItem 9.01. Other Events.
On August 14, 2017, Ophthotech Corporation issued a press release announcing the results from its third Phase 3 clinical trial of Fovista® in wet age related macular degeneration. A copy of this press release is attached hereto as Exhibit99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits:
99.1 Press Release dated August14, 2017.
Ophthotech Corp. ExhibitEX-99.1 2 exhibit99108142017.htm EXHIBIT 99.1 Exhibit Ophthotech Announces Results from Third Phase 3 Trial of Fovista® in Wet Age-Related Macular DegenerationNEW YORK,…To view the full exhibit click here
About OPHTHOTECH CORPORATION (NASDAQ:OPHT)
Ophthotech Corporation is a biopharmaceutical company. The Company specializes in the development of therapeutics to treat diseases of the back of the eye, with a focus on developing therapeutics for age-related macular degeneration (AMD). Its advanced product candidate is Fovista, which is for use in combination with anti-vascular endothelial growth factor (VEGF) drugs. It is also developing its product candidate Zimura for the treatment of patients with geographic atrophy, a form of dry AMD, in combination with VEGF therapy for the treatment of polypoidal choroidal vasculopathy (PCV). Fovista is being tested in Phase III clinical development. In addition, it has initiated additional clinical trials to evaluate the potential additional benefits of Fovista administered in combination with anti-VEGF drugs in wet AMD patients, known as Fovista Expansion Studies. Zimura has completed a small, multicenter, uncontrolled, open label Phase I/IIa clinical trial.
